Context: SARS-COV2 infection, the respiratory febrile disease firstly described in China in December 2019, which was declared a pandemic on March 11th, 2020, is associated with multiple air and fluid collections. Spontaneous hemopneumothorax in coronavirus disease 19 (COVID 19) patients is a rare clinical entity described as an unusual complication of severe COVID 19 pneumonia. Objective: The authors used the database of a single COVID 19 treatment center only. In our case series, we encountered a patient with particular hemopneumothorax features that we have decided to present. Method: A 51-year-old non-smoker male with fever and cough lasting for 7 days was admitted to the dedicated COVID 19 unit of "Dr. Carol Davila" Central University Military Hospital Bucharest. The patient developed hemopneumothorax on the 14 th day since the beginning of the symptoms. The thoracic surgeon performed pleural drainage through minimal pleurotomy allowing the evacuation of both air and fluid. Results: Post interventional computed tomography scan showed the remission of hemopneumothorax. The favorable evolution and the negative SARS COV2 screening throat swab test allowed the discharge of the patient on the 25th day after initial diagnosis. Conclusions: In certain situations, COVID 19 pneumopathy may lead to hemopneumothorax with unpredictable evolution, and only a fast therapeutic intervention can save the patient's life.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.